Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.

IF 33.7 1区 医学 Q1 Medicine
Miwako Kobayashi, Tamara Pilishvili, Jennifer L Farrar, Andrew J Leidner, Ryan Gierke, Namrata Prasad, Pedro Moro, Doug Campos-Outcalt, Rebecca L Morgan, Sarah S Long, Katherine A Poehling, Adam L Cohen
{"title":"Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.","authors":"Miwako Kobayashi, Tamara Pilishvili, Jennifer L Farrar, Andrew J Leidner, Ryan Gierke, Namrata Prasad, Pedro Moro, Doug Campos-Outcalt, Rebecca L Morgan, Sarah S Long, Katherine A Poehling, Adam L Cohen","doi":"10.15585/mmwr.rr7203a1","DOIUrl":null,"url":null,"abstract":"<p><strong>This report compiles and summarizes all published recommendations from cdc’s advisory committee on immunization practices (acip) for use of pneumococcal vaccines in adults aged ≥19 years in the united states. this report also includes updated and new clinical guidance for implementation from cdc: </strong></p><p><strong>Before 2021, acip recommended 23-valent pneumococcal polysaccharide vaccine (ppsv23) alone (up to 2 doses), or both a single dose of 13-valent pneumococcal conjugate vaccine (pcv13) in combination with 1–3 doses of ppsv23 in series (pcv13 followed by ppsv23), for use in u.s. adults depending on age and underlying risk for pneumococcal disease. in 2021, two new pneumococcal conjugate vaccines (pcvs), a 15-valent and a 20-valent pcv (pcv15 and pcv20), were licensed for use in u.s. adults aged ≥18 years by the food and drug administration: </strong></p><p><strong>Acip recommendations specify the use of either pcv20 alone or pcv15 in series with ppsv23 for all adults aged ≥65 years and for adults aged 19–64 years with certain underlying medical conditions or other risk factors who have not received a pcv or whose vaccination history is unknown. in addition, acip recommends use of either a single dose of pcv20 or ≥1 dose of ppsv23 for adults who have started their pneumococcal vaccine series with pcv13 but have not received all recommended ppsv23 doses. shared clinical decision-making is recommended regarding use of a supplemental pcv20 dose for adults aged ≥65 years who have completed their recommended vaccine series with both pcv13 and ppsv23: </strong></p><p><strong>Updated and new clinical guidance for implementation from cdc includes the recommendation for use of pcv15 or pcv20 for adults who have received ppsv23 but have not received any pcv dose. the report also includes clinical guidance for adults who have received 7-valent pcv (pcv7) only and adults who are hematopoietic stem cell transplant recipients: </strong></p>","PeriodicalId":51328,"journal":{"name":"Mmwr Recommendations and Reports","volume":null,"pages":null},"PeriodicalIF":33.7000,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495181/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mmwr Recommendations and Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.rr7203a1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

This report compiles and summarizes all published recommendations from cdc’s advisory committee on immunization practices (acip) for use of pneumococcal vaccines in adults aged ≥19 years in the united states. this report also includes updated and new clinical guidance for implementation from cdc:

Before 2021, acip recommended 23-valent pneumococcal polysaccharide vaccine (ppsv23) alone (up to 2 doses), or both a single dose of 13-valent pneumococcal conjugate vaccine (pcv13) in combination with 1–3 doses of ppsv23 in series (pcv13 followed by ppsv23), for use in u.s. adults depending on age and underlying risk for pneumococcal disease. in 2021, two new pneumococcal conjugate vaccines (pcvs), a 15-valent and a 20-valent pcv (pcv15 and pcv20), were licensed for use in u.s. adults aged ≥18 years by the food and drug administration:

Acip recommendations specify the use of either pcv20 alone or pcv15 in series with ppsv23 for all adults aged ≥65 years and for adults aged 19–64 years with certain underlying medical conditions or other risk factors who have not received a pcv or whose vaccination history is unknown. in addition, acip recommends use of either a single dose of pcv20 or ≥1 dose of ppsv23 for adults who have started their pneumococcal vaccine series with pcv13 but have not received all recommended ppsv23 doses. shared clinical decision-making is recommended regarding use of a supplemental pcv20 dose for adults aged ≥65 years who have completed their recommended vaccine series with both pcv13 and ppsv23:

Updated and new clinical guidance for implementation from cdc includes the recommendation for use of pcv15 or pcv20 for adults who have received ppsv23 but have not received any pcv dose. the report also includes clinical guidance for adults who have received 7-valent pcv (pcv7) only and adults who are hematopoietic stem cell transplant recipients:

Abstract Image

≥19岁成年人肺炎球菌疫苗:免疫实践咨询委员会的建议,美国,2023年。
本报告汇编并总结了疾病预防控制中心免疫实践咨询委员会(acip)就美国≥19岁成年人使用肺炎球菌疫苗提出的所有建议。该报告还包括cdc实施的最新临床指南:在2021年之前,acip建议单独使用23价肺炎球菌多糖疫苗(ppsv23)(最多2剂),或同时使用单剂13价肺炎球菌结合疫苗(pcv13)和1-3剂ppsv23系列疫苗(pcv13和ppsv23之后),根据年龄和肺炎球菌疾病的潜在风险在美国成年人中使用。2021年,两种新的肺炎球菌结合疫苗(pcvs),一种是15价的,另一种是20价的(pcv15和pcv20),美国食品药品监督管理局批准在≥18岁的美国成年人中使用:Acip建议规定,对于所有≥65岁的成年人,以及患有某些潜在疾病或其他风险因素的19-64岁未接种pcv或疫苗接种史未知的成年人,单独使用pcv20或与ppsv23联合使用pcv15。此外,acip建议,对于已经开始接种pcv13肺炎球菌疫苗系列但尚未接种所有推荐剂量的ppsv23的成年人,使用单剂pcv20或≥1剂ppsv23。建议对年龄≥65岁且已完成推荐的pcv13和ppsv23疫苗系列的成年人使用补充pcv20剂量进行共同临床决策:cdc更新和新的临床实施指南包括对已接种ppsv23但未接种任何pcv剂量的成年人使用pcv15或pcv20的建议。该报告还包括对仅接受7价pcv(pcv7)的成年人和造血干细胞移植受者的成年人的临床指导:
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Mmwr Recommendations and Reports
Mmwr Recommendations and Reports PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
36.00
自引率
0.00%
发文量
3
期刊介绍: The MMWR series of publications is published by the Office of Science, Centers for Disease Control and Prevention (CDC), U.S. The MMWR Recommendations and Reports contain in-depth articles that relay policy statements for prevention and treatment in all areas in the CDC’s scope of responsibility (e.g., recommendations from the Advisory Committee on Immunization Practices).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信